Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study

Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stewart J Tepper, Juanzhi Fang, Lujia Zhou, Pamela Vo, Ahmad Abdrabboh, Mrudula Glassberg, Matias Ferraris
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Therapeutics. Pharmacology RM1-950 Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/c34ea09e7919453a84bd75c1b089350f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c34ea09e7919453a84bd75c1b089350f
record_format	dspace
spelling	oai:doaj.org-article:c34ea09e7919453a84bd75c1b089350f2021-11-18T05:03:19ZComparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study2515-816310.1177/25158163211040061https://doaj.org/article/c34ea09e7919453a84bd75c1b089350f2021-09-01T00:00:00Zhttps://doi.org/10.1177/25158163211040061https://doaj.org/toc/2515-8163Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) on acute medication usage and healthcare resource utilization (HCRU) among migraine patients. Methods: This retrospective US claims analysis included patients (≥18 years) diagnosed with migraine who initiated erenumab (May 01, 2018 and September 30, 2019) or OMPM (May 01, 2016 and October 31, 2017). Cohorts were matched 1:1 using the propensity score (PS) method with stratification. Acute medication usage, HCRU, and a composite endpoint of 1) outpatient visit with a migraine diagnosis and associated acute medication claim, 2) hospital admission with a primary migraine diagnosis, or 3) emergency room visit with a primary migraine diagnosis were assessed 6 months post-treatment initiation. Results: Following PS matching, both cohorts included 2,343 patients. At 6 months, erenumab was associated with significantly less acute medication usage versus OMPM, including number of types of acute medications used, number of claims per person, and proportion of patients using acute medication. HCRU and number of composite events were also significantly lower among erenumab users. Conclusion: Erenumab is more effective than OMPM at reducing acute medication usage and HCRU among migraine patients. Trial registration: N/A.Stewart J TepperJuanzhi FangLujia ZhouPamela VoAhmad AbdrabbohMrudula GlassbergMatias FerrarisSAGE PublishingarticleTherapeutics. PharmacologyRM1-950Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENCephalalgia Reports, Vol 4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950 Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Therapeutics. Pharmacology RM1-950 Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Stewart J Tepper Juanzhi Fang Lujia Zhou Pamela Vo Ahmad Abdrabboh Mrudula Glassberg Matias Ferraris Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
description	Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) on acute medication usage and healthcare resource utilization (HCRU) among migraine patients. Methods: This retrospective US claims analysis included patients (≥18 years) diagnosed with migraine who initiated erenumab (May 01, 2018 and September 30, 2019) or OMPM (May 01, 2016 and October 31, 2017). Cohorts were matched 1:1 using the propensity score (PS) method with stratification. Acute medication usage, HCRU, and a composite endpoint of 1) outpatient visit with a migraine diagnosis and associated acute medication claim, 2) hospital admission with a primary migraine diagnosis, or 3) emergency room visit with a primary migraine diagnosis were assessed 6 months post-treatment initiation. Results: Following PS matching, both cohorts included 2,343 patients. At 6 months, erenumab was associated with significantly less acute medication usage versus OMPM, including number of types of acute medications used, number of claims per person, and proportion of patients using acute medication. HCRU and number of composite events were also significantly lower among erenumab users. Conclusion: Erenumab is more effective than OMPM at reducing acute medication usage and HCRU among migraine patients. Trial registration: N/A.
format	article
author	Stewart J Tepper Juanzhi Fang Lujia Zhou Pamela Vo Ahmad Abdrabboh Mrudula Glassberg Matias Ferraris
author_facet	Stewart J Tepper Juanzhi Fang Lujia Zhou Pamela Vo Ahmad Abdrabboh Mrudula Glassberg Matias Ferraris
author_sort	Stewart J Tepper
title	Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
title_short	Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
title_full	Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
title_fullStr	Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
title_full_unstemmed	Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
title_sort	comparative effectiveness of erenumab versus oral preventive medications among migraine patients: a us claims database study
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/c34ea09e7919453a84bd75c1b089350f
work_keys_str_mv	AT stewartjtepper comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT juanzhifang comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT lujiazhou comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT pamelavo comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT ahmadabdrabboh comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT mrudulaglassberg comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT matiasferraris comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy
_version_	1718424938874929152

Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study

Ejemplares similares